Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component ...

the Hip business of Zimmer Biomet is projected to grow 2.6% in the first quarter on a year-over-year basis. Within the Knee business, apart from a strong recovery in elective procedures ...

Zimmer Biomet CEO Ivan Tornos said he anticipates ASCs to be a major support for growing orthopedic case volumes during the Barclays 27th Annual Global Healthcare Conference. “That is a huge tailwind ...

Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...

Individuals with limited mobility due to hip, knee, shoulder or other joint pain, can share their stories as part of the joint campaign. GlobalData analysis places Zimmer Biomet as one of the ...

The leader in the worldwide market for hip and knee joints is Zimmer Biomet (NYSE: ZBH), with 33% of the market, followed by Stryker with 22%. The UK’s Smith & Nephew is in fourth place with 11%.